Elekta launches Versa HD


Elekta has launched Versa HD, an advanced linear accelerator system designed to improve patient care and treat a broader spectrum of cancers. Featuring high precision beam shaping and tumour targeting, Versa HD also possesses new capabilities designed to maximise healthcare system resources and deliver sophisticated therapies without compromising treatment times.

The integrated Versa HD system allows clinicians to deliver conventional therapies to treat a wide range of tumours throughout the body, while also enabling treatment of highly complex cancers that require extreme targeting precision. Integrated with Elekta's recently-launched Agility 160-leaf multileaf collimator (MLC), Versa HD provides highly conformal beam shaping, a critical requirement for maximising the dose to the target while also preserving surrounding healthy tissues. This high targeting accuracy is available over a large field-of-view, permitting delivery of high-definition (HD) beams to a wide spectrum of complex targets. Historically, HD beam shaping was often mechanically limited to only small target therapies. Versa HD with Agility allows clinicians to deliver extremely precise beam contouring for both small and large targets.

Capable of delivering radiation doses three times faster than previous generation Elekta linear accelerators, Versa HD harnesses the ultra-fast leaf speeds of Agility MLC. With this combination, clinicians can take advantage of higher dose rate delivery, potentially enabling greater capabilities for sophisticated therapies, including stereotactic radiosurgery, stereotactic radiotherapy and volumetric modulated arc therapy.

To reduce environmental impact and operating costs, Versa HD consumes up to 30 per cent less energy than other delivery systems. The system is not available for sale or distribution in all markets. Elements of Versa HD are pending FDA 510(k) clearance.

This article is tagged to:
Sector: Medical Devices
Geography: Europe, Sweden

Access all of our latest analysis, data and forecasts - request a trial